Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor. Serum is the preferred specimen.
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
New York DOH Approval Status
Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Hemolyzed, contaminated, or severely lipemic specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month
Less than 1:1
CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.
Laboratory Developed Test (LDT)
If CV2.1 Antibody IgG Screen by IFA, CSF is positive, then CV2.1 Antibody IgG Titer, CSF will be added. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|3002259||CV2.1 Ab IgG Screen, CSF||53707-6|
- Cerebellar degeneration
- Collapsin response-mediator protein 5
- Cranial neuropathy
- Peripheral neuropathy
- Vision loss